Dear All, Explaining AMR to our colleagues is not easy! I wrote in a 30 Oct 2019 newsletter about what Wellcome Trust learned on this point when they interviewed 12,000 people in Germany, India, Japan, Kenya, the UK, the USA and Thailand — in brief, there are universal themes that improve the likelihood that your message will
Note: Newsletter now updated to include the communique from the G7 Finance Ministers! Dear All, The G7 met in Oxford this past week and we now have communiques released from by both the Health and Finance Ministers. Let’s look first at the two fascinating statements from the Health Ministers: A general communique that includes multiple
Dear All, I was made aware today of this important paper and wanted to share it promptly: Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, Goyal JP, Tadepalli K, Mathur P, Venkateswaran R, Venkatasubramanian R, Khadanga S, Bhattacharya S, Mukherjee S, Baveja S, Sistla S, Panda S, Walia K. Secondary Infections
Dear All, I have recently become aware of MTEC (Medical Technology Enterprise Consortium), a 501(c)(3) nonprofit organization designed to accelerate the translation of medical technologies into solutions that prevent and treat injuries and restore the health of United States military personnel. MTEC is a public-private collaboration between the U.S. federal government and the businesses and
Dear All, It’s been a busy day! Hot on the heels of today’s Duke-Margolis webinar on combatting AMR during which Senator Bennet said that he expects the PASTEUR Act to come to legislative approval this year based on strong bipartisan support (Senator Bennet is working with Senator Young), we have an announcement this afternoon that BARDA
Dear All, GNA NOW (part of the IMI AMR Accelerator; this 25 Mar 2021 press release is a good overview of the AMR Accelerator) has just announced an open call to identify a novel mechanism candidate antibacterial to add to its portfolio. For those not familiar with it, the IMI AMR Accelerator is a 295 m€ IMI program
Dear All (and note the related 28 Nov 2020 newsletter), Stella Kyriakides, the European Commissioner for Health and Food Safety, made some really interesting statements before the European Parliament’s health committee (ENVI) on Thursday of last week (22 April). Per this Exchange of Views on the EP’s multimedia center and this news report, here are some
Dear All, Three global conversations to put on your listen-to-this list! One is this coming week, one is during ECCMID, and one is a video you can listen to now! First up and happening in just a few days on Thursday 29 Apr (10a-6p EST), please mark your calendar for a UN General Assembly High-Level interactive
Dear All, WHO have today updated their 2019 clinical/preclinical pipeline review by releasing their 2020 analyses of both the clinical and pre-clinical antibacterial product pipelines (the new 2020 report, the press release). Their 2020 review of antibacterial products in Phase 1 and beyond covers both traditional (n = 43) and non-traditional products (n = 27)
Dear All, FDA, NIAID and CDC have announced a public workshop on development considerations of antimicrobial drugs for the treatment of gonorrhea. The workshop will cover both nonclinical (preclinical) and clinical trial design considerations: Animal models Clinical pharmacology considerations Trial design considerations for gonorrhea, such as enrollment strategies, choice of comparators and site of infection.